Free Trial
→ Musk is burning $2.5 billion a quarter on AI. One company holds the key. (From Behind the Markets) (Ad)tc pixel
NASDAQ:PMCB

Nuvilex Q4 2025 Earnings Report

Nuvilex logo
$0.75 -0.05 (-5.76%)
As of 03:18 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nuvilex EPS Results

Actual EPS
-$0.25
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuvilex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvilex Announcement Details

Quarter
Q4 2025
Date
8/8/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nuvilex's next earnings date is estimated for Wednesday, July 1, 2026, based on past reporting schedules.

Conference Call Resources

Nuvilex Earnings Headlines

Nuvilex Inc. (NASDAQ:PMCB) Sees Large Increase in Short Interest
May 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30807333
Nuvilex (NASDAQ:PMCB) Trading Down 3.3% - Time to Sell?
May 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30804623
Musk's shopping list: batteries ✓ solar ✓ data ✓ power ___
Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity for $2.6 billion and Twitter for $44 billion. Now one small company makes the equipment his Colossus supercomputer - a million GPUs consuming nearly $1 billion a month in power - cannot run without. Analyst Dylan Jovine has identified the name and ticker. For investors who own shares before a potential move, the math could be significant.tc pixel
June 2 at 1:00 AM  |  Behind the Markets (Ad)
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 2, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250902025594/en/pharmacyte-biotech-inc.-increases-stake-in-tnf-pharmaceuticals-around-recent-license-for-breakthrough-light-speed-computing-platform-for-use-in-cryptocurrency-applications/
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250820055624/en/PharmaCyte-Biotech-Inc.-Announces-Closing-of-7-Million-Financing/
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
August 18, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250818528622/en/pharmacyte-biotech-inc.-announces-7-million-capital-raise-led-by-existing-investors/
See More Nuvilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvilex and other key companies, straight to your email.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex (NASDAQ:PMCB), Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

View Nuvilex Profile
Earnings Tools